All In Biotech

Drug Trial Radar · NCT07663526

Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

A Multicenter, Single-Arm Study to Evaluate the Effectiveness and Safety of Tabellvi® (Adalimumab) in Chinese Adult Subjects With Moderate to Severe Active Crohn's Disease in the Real-World Setting

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 23, 2026

Primary completion

Dec 2028

Study completion Mar 2029

Sponsor

Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled. The primary endpoints include the incidence rates of adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs) and serious ADRs, as well as the proportion of subjects achieving clinical remission (CDAI score \< 150) at Week 26.

Conditions

  • Crohn's Disease

Interventions

  • TyboWe® Adalimumab InjectionDrug

    Adalimumab is a human anti-tumour necrosis factor-alpha monoclonal antibody that inhibits the downstream inflammatory cascade by blocking TNF-α, a core inflammatory factor in psoriasis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serious Adverse Event (SAE)Time frame: Baseline up to 54 weeks
  2. Adverse Event (AE)Time frame: Baseline up to 54 weeks
  3. Adverse Drug Reaction (ADR)Time frame: Baseline up to 54 weeks
  4. Serious Adverse Drug ReactionTime frame: Baseline up to 54 weeks
  5. Clinical remission (CDAI < 150)Time frame: At Week 26 post-dose

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Fuyang People's Hospital

    Fuyang, Anhui, China · Not yet recruiting

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Zhoukou Central Hospital

    Zhoukou, Henan, China · Not yet recruiting

  • Huai'an First People's Hospital

    Huaian, Jiangsu, China · Not yet recruiting

  • Yancheng No.1 People's Hospital

    Yancheng, Jiangsu, China · Not yet recruiting

  • Meihekou Central Hospital

    Meihekou, Jilin, China · Not yet recruiting

  • Shanghai Jiao Tong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.